GLG News by Ophthalmologists

The Genetic Information Nondiscrimination Act (GINA), which will soon become law, will protect Americans who choose to have genetic testing against the fear of discrimination by employers and health insurers. The idea of personalized medicine can not become a reality with out the passage of GINA.

The FDA report and scrutiny of LASIK complaints reveals what consientious LASIK surgeons have known for years:  Not everyone who walks through your doors is a good lasik candidate and you should not laser everyone.  About 1 out of 4 patients that consider lasik are actually good candidates...

The media reporting on the FDA hearings on LASIK has generally highlighted unhappy patients' stories and the comments of FDA officials and panel members.  However, The Washington Post's Lauran Neergard has written an insightful article that foresees an important future trend in refractive surgery....

A new model of the increasing popular Ex-Press Shunt is quite effective in an early study.  Its is quite safe and effective; and simpler substitute for trabeculectomy.  It could be the first line  in the surgical management of glaucoma.

Alcon (ACL) reported positive interim results for their injectable medication for glaucoma.  A single injection of anecortave acetate  resulted in control of IOP at the three month follow up.  This could be a promising medication for IOP control in glaucoma.

The light adjustable lens is a lens implant that is placed in the eye like a tradition intraocular lens during cataract surgery.  The unique difference is that it can be treated with a special light after surgical implant (weeks to months later) to correct any residual refractive errors or to fine...

1. AMD 2. Anti VEG 3. Visudyne

In many respects, it is good that this trial was done.  For many years, retinal physicians had used Avastin injections preferentially over Lucentis for the treatment of AMD because of the vast difference in cost.

It is a common business practice for companies to wine and dine potential clients in an effort to secure new business contracts.  This is not considered to be a bribe, it is considered good business practice.  Is Stryker's case that different? Physicians go into practice for many reasons. ...

I agree...the present situation is really quite absurd...in most practices...IF a third party is willing to pay for Lucentis...patients usually get Lucentis...if patients have to pay themselves...they usually receive Avastin...despite there not being a shred of convincing evidence that Lucentis is superior...